ABSTRACT
Objective Time in targeted blood glucose range (TIR) 70-140 mg/dL has been associated with an increased risk of mortality in critically ill patients. Nevertheless, it remains unclear whether TIR is associated with 28-day mortality in critically ill patients under glycemic control with a less tight target glucose range of 70-180 mg/dL. We aimed to assess whether TIR 70-180 mg/dL was associated with 28-day mortality and to identify the optimal TIR.
Design A retrospective observational study.
Setting Data from a tertiary care centre in Japan, from 1 January 2016 through 31 October 2019.
Participants 1,230 adult patients admitted to the intensive care unit for more than three days.
Outcome measure The primary outcome was 28-day mortality.
Results Of 1,230 patients, patients with HbA1c ≥6.5% had a higher 28-day mortality than those with <6.5% (32.0% vs. 22.7%; p=0.003). In the multivariate logistic regression, TIR <80% was associated with an increased risk of 28-day mortality in patients with HbA1c <6.5% with an adjusted odds ratio (OR) of 1.88 (95% confidence interval [CI]: 1.36-2.61). When using 10% incremental TIR as a categorical variable, lower TIR was associated with worse 28-day mortality compared to TIR ≥90% in patients with HbA1c <6.5% (e.g., adjusted OR of TIR <60%, 3.62 [95%CI 2.36-5.53]). Similar associations were found in the analyses using the COX proportional hazards model. In addition, sensitivity analyses using TIR of the first three days showed that the overall associations were consistent with primary analyses.
Conclusions Our study demonstrated that lower TIR 70-180 mg/dL was associated with higher 28-day mortality in nondiabetic critically ill patients.
Article Summary
Strengths and limitations of this studyThis is the first study to evaluate the association between less tight TIR (70-180 mg/dl) and mortality in critically ill patients.
We found consistent results in the analyses using logistic regression model and Cox proportional hazard model.
The primary findings were also observed in the analysis using TIR in the first three days.
We did not use a continuous glucose monitoring device to calculate TIR.
Due to the nature of the single-centre study design, the generalizability of the findings might be limited.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There is no funder/sponsor support for design and conduct of the study, for collection, management, analysis, and interpretation of the data, for preparation, review, or approval of the manuscript, or for decisions to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee of Hitachi General Hospital
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The email address of each author: Tadahiro Goto: tag695{at}mail.harvard.edu
Toru Shirakawa: shirakawa{at}pbhel.med.osaka-u.ac.jp
Tomohiro Sonoo: tomohiro.sonoo{at}txpmedical.com
Naoki Kanda: nakanda-tky{at}umin.ac.jp
Hidehiko Nakano: hinakano-tky{at}umin.ac.jp
Yuji Takahashi: yuji.mail{at}icloud.com
Hideki Hashimoto: hideg1018{at}gmail.com
Kensuke Nakamura: knakamura-tky{at}umin.ac.jp
Data Availability
The datasets used and analysed during the current study are available from the corresponding author on reasonable request.
